Question 1

What are the potential benefits of participating in this trial compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) clinical trial (NCT06393374). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my eligibility be determined, and what tests will I need to undergo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) clinical trial (NCT06393374). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) clinical trial (NCT06393374). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) clinical trial (NCT06393374). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) clinical trial (NCT06393374). Contact the study team or your healthcare provider for specific answers.

Question 6

Can you explain the process of randomization and what it means for my treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) clinical trial (NCT06393374). Contact the study team or your healthcare provider for specific answers.

What this study is about